Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01434758
Other study ID # 09TB
Secondary ID
Status Completed
Phase N/A
First received April 6, 2011
Last updated November 13, 2016
Start date April 2011
Est. completion date September 2015

Study information

Verified date November 2013
Source Oxford University Clinical Research Unit, Vietnam
Contact n/a
Is FDA regulated No
Health authority Vietnam: Ministry of Health
Study type Observational

Clinical Trial Summary

Detection of M. tuberculosis in clinical specimens of children has a low sensitivity because specimens are either difficult to collect or contain low levels of M. tuberculosis. Diagnostic criteria are non-specific and culture confirmation is challenging, as sputum samples are not often obtainable from small children and specimens typically have low yield. Although children are typically thought to have paucibacillary disease, they are at greater risk for dissemination of TB. This may allow for detection of Mycobacterium tuberculosis from other bodily fluids than sputum or gastric aspirate, including blood and urine. Unfortunately, little is known about the overall yield from these various specimens. From pilot data collected among adults and children in Tugela Ferry, we know that it is feasible to collect and test various bodily fluid specimens for TB culture. This study aim to test the hypothesis that blood and urine cultures will detect Mycobacterium tuberculosis from children suspected of disseminated TB, and that a proportion of these non-sputum bodily fluids will detect both drug-susceptible and drug-resistant tuberculosis when sputum or gastric culture does not.


Description:

Tuberculosis (TB) is a major cause of morbidity and mortality among children in developing nations. Symptom-based diagnostic criteria are non-specific and culture confirmation is challenging, as sputum samples are often believed to be to too cumbersome to obtain from small children and specimens typically have low yield due to the paucibacillary nature of pediatric TB. Culture confirmation may be obtained in as few as 10% of cases of suspected pediatric TB. For these reasons, the true extent of the (drug-resistant) TB epidemic in children is unknown. Thus, either clinicians begin empiric treatment without diagnosis or no treatment is given at all. Current laboratory methods, if available at all in resource poor settings, employ smears from expectorated sputa or gastric aspirates which have low sensitivity in children. While more rapid diagnostic techniques such as PCR based tests have been developed, there is still poor sensitivity in children. Improving the diagnosis of pediatric TB must focus on better efforts, including more aggressive strategies to uncover disseminated disease.

Culture confirmation of disseminated disease can be obtained from blood, urine, cerebrospinal fluid (CSF), peritoneal and pleural fluid, or purulent material from lymph node aspirates, abscesses or otorrhea. Unfortunately, little is known about the overall yield from these various specimens in children. From pilot data collected among children at NHP, we know that it is feasible to collect and test various bodily fluid specimens for TB culture.

Although WHO guidelines encourage body fluid collection in order to make a diagnosis of TB in children, at present in NHP, blood and urine cultures are not obtained for mycobacterial culture. However, this study seeks to demonstrate that routine investigation of blood and urine will augment the yield of traditional sputum culture for children in whom disseminated disease is more likely. Improved culture confirmation will allow DST and a more accurate description of the drug-resistant TB epidemic for children in the region.


Recruitment information / eligibility

Status Completed
Enrollment 560
Est. completion date September 2015
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group N/A to 15 Years
Eligibility Inclusion Criteria:

- Aged 0-15, presenting at NHP;

- Unexplained fever for more than 2 weeks; and

- Any form of TB suspected based on at least two of the following findings:

- unexplained cough for more than 2 weeks

- radiographic findings suggestive of tuberculosis.

- failure to thrive/weight loss

- enlarged non-tender lymph nodes or lymph node abscess, especially of the neck

- signs of meningitis with prodromal stage of at least one week

- HIV positive

- malnourished

- TB contact history

- Clinical judgment treating doctor.

- Relevant material (sputum or gastric aspirate, blood, and urine) available for microbiological diagnosis.

- Informed consent obtained from the patient's legal guardian(s).

Exclusion Criteria:

- Age >15 years

- Diagnosed or treated for TB in the past year, received drugs effective against TB in last 3 months.

- Clinical contra-indications to collect the required study specimens

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Vietnam National Hospital of Pediatrics Hanoi

Sponsors (2)

Lead Sponsor Collaborator
Oxford University Clinical Research Unit, Vietnam National Hospital of Pediatrics, Vietnam

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic yield of TB culture Number of positive TB cultures versus number of positive TB direct smears for expectorate and/or gastric aspirate. At baseline - day 1 of study No
Primary Diagnostic yield of TB culture Number of positive TB cultures versus number of positive MODS cultures for expectorate and/or gastric aspirate. At baseline - day 1 of study No
Primary Diagnostic yield of urine versus expectorate or gastric aspirate for TB culture Number of positive TB cultures in urine versus expectorate and/or gastric aspirate. At baseline - day 1 of study No
See also
  Status Clinical Trial Phase
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Completed NCT04545164 - Computer Aided Screening for Tuberculosis in Low Resource Environments N/A
Recruiting NCT05766267 - Short-course Regimens for the Treatment of Pulmonary Tuberculosis Phase 2/Phase 3
Recruiting NCT05756582 - Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
Enrolling by invitation NCT04988984 - Development of Automated Molecular Diagnostic Platform for Tuberculosis Diagnosis (New Assay TB)
Recruiting NCT04148053 - Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis
Recruiting NCT01689831 - Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose) Phase 2
Completed NCT05945498 - Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years Phase 1
Not yet recruiting NCT06352970 - Effects of Tuberculosis Infection on Development and Function of the Placenta
Recruiting NCT04575519 - Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis Phase 2
Recruiting NCT05413551 - Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention Phase 1
Recruiting NCT03941210 - Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
Completed NCT04494516 - Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial
Withdrawn NCT03265977 - A Phase II Study of H56:IC31 in Healthy Adolescents Phase 2
Recruiting NCT05069688 - Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin Phase 1
Suspended NCT05330884 - BCG Revaccination in Children and Adolescents Phase 3
Recruiting NCT05342064 - Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service N/A
Recruiting NCT05236452 - Effect of Integrating Traditional Tuberculosis Care With Modern Health Care on Case Detection N/A
Recruiting NCT05443178 - Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy Phase 1
Recruiting NCT05122026 - Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Phase 1/Phase 2

External Links